传染病治疗市场－全球产业规模、份额、趋势、机会和预测，依疾病类型、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球传染病治疗市场规模为676.4亿美元，预计到2030年将以7.74%的复合年增长率增长至1058亿美元。全球传染病治疗市场涵盖用于预防、治疗和控制由致病微生物（包括细菌、病毒、真菌和寄生虫）引起的疾病的药物和医疗干预措施。推动市场扩张的关键因素包括全球传染病流行率的上升、抗菌素抗药性持续存在的挑战，以及为满足未被满足的医疗需求而不断增加的研发投入。诊断技术的不断进步，使得疾病的早期和精准识别成为可能，也进一步促进了市场成长。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球传染病治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型（爱滋病、肝炎、流感、结核病、疟疾、人类乳突病毒、其他）
  • 依最终用途（医院、诊所、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美传染病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲传染病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区传染病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲传染病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲传染病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球传染病治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Novartis AG
• Gilead Sciences Inc
• GSK PLC
• Johnson & Johnson Innovative Medicine
• F Hoffmann-La Roche AG
• BioCryst Pharmaceuticals Inc
• Merck & Co Inc
• Boehringer Ingelheim International GmbH

第十六章：策略建议

第17章调查会社について・免责事项

The Global Infectious Disease Therapeutics Market, valued at USD 67.64 Billion in 2024, is projected to experience a CAGR of 7.74% to reach USD 105.80 Billion by 2030. The Global Infectious Disease Therapeutics Market encompasses pharmaceutical agents and medical interventions designed for the prevention, treatment, and management of illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. Key drivers supporting market expansion include the increasing global prevalence of infectious diseases, the persistent challenge of antimicrobial resistance, and growing investments in research and development to address unmet medical needs. Further impetus comes from continuous advancements in diagnostic technologies enabling earlier and more precise disease identification.

Key Market Drivers

The increasing global burden of infectious diseases fundamentally drives market expansion, creating persistent and widespread demand for effective treatments and preventative measures. Diseases like tuberculosis and malaria continue to exact a significant toll on global health, necessitating ongoing research and development into novel pharmacological agents and improved therapeutic strategies. The sheer scale of these challenges ensures a consistent market for diagnostics, drugs, and vaccines, as healthcare systems grapple with endemic infections and outbreaks. According to the World Health Organization, in its Global Tuberculosis Report 2023, an estimated 10.6 million people fell ill with tuberculosis worldwide in 2022, underscoring the critical need for continued therapeutic interventions. This sustained disease pressure compels pharmaceutical companies to invest in developing new therapies to address unmet medical needs.

Key Market Challenges

A significant challenge impeding the growth of the Global Infectious Disease Therapeutics Market is the substantial costs associated with drug discovery and development. Bringing new pharmaceutical agents from initial research to market approval demands extensive financial outlays for preclinical studies, multiple phases of clinical trials, and manufacturing infrastructure. This immense capital requirement significantly raises the barrier to entry for innovators and imposes considerable financial risk on companies, influencing strategic decisions about which therapeutic areas to prioritize.

Key Market Trends

The application of Artificial Intelligence (AI) in drug discovery is significantly reshaping the development landscape for infectious disease therapeutics. AI algorithms are increasingly employed to accelerate the identification of novel drug targets, optimize compound synthesis, and predict drug efficacy and toxicity with greater precision and speed, thereby reducing the time and cost associated with traditional drug development. This technological integration is poised to streamline the discovery of urgently needed treatments for evolving pathogens. According to a survey from Rackspace Technology and Dell/VMware, conducted in October 2023, two out of three pharmaceutical companies (67%) planned to increase their investment in information technology, including artificial intelligence, over the subsequent 12 months. This substantial industry-wide commitment to AI is expected to catalyze innovation across all therapeutic areas, including infectious diseases, by enhancing the efficiency of research and development pipelines.

Key Market Players

• Novartis AG
• Gilead Sciences Inc
• GSK PLC
• Johnson & Johnson Innovative Medicine
• F Hoffmann-La Roche AG
• BioCryst Pharmaceuticals Inc
• Merck & Co Inc
• Boehringer Ingelheim International GmbH

Report Scope:

In this report, the Global Infectious Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Therapeutics Market, By Disease Type:

• HIV
• Hepatitis
• Influenza
• TB
• Malaria
• HPV
• Others

Infectious Disease Therapeutics Market, By End Use:

• Hospitals
• Clinics
• Others

Infectious Disease Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infectious Disease Therapeutics Market.

Available Customizations:

Global Infectious Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others)
  • 5.2.2. By End Use (Hospitals, Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Infectious Disease Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Infectious Disease Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Infectious Disease Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Infectious Disease Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By End Use

7. Europe Infectious Disease Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Infectious Disease Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By End Use
  • 7.3.2. France Infectious Disease Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Infectious Disease Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Infectious Disease Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Infectious Disease Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By End Use

8. Asia Pacific Infectious Disease Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Infectious Disease Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Infectious Disease Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Infectious Disease Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Infectious Disease Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Infectious Disease Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By End Use

9. Middle East & Africa Infectious Disease Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Infectious Disease Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By End Use
  • 9.3.2. UAE Infectious Disease Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. South Africa Infectious Disease Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By End Use

10. South America Infectious Disease Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Infectious Disease Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By End Use
  • 10.3.2. Colombia Infectious Disease Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By End Use
  • 10.3.3. Argentina Infectious Disease Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Infectious Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Gilead Sciences Inc
• 15.3. GSK PLC
• 15.4. Johnson & Johnson Innovative Medicine
• 15.5. F Hoffmann-La Roche AG
• 15.6. BioCryst Pharmaceuticals Inc
• 15.7. Merck & Co Inc
• 15.8. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer